Status:
RECRUITING
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
Lead Sponsor:
NYU Langone Health
Conditions:
Prostate Cancer
Eligibility:
MALE
40-95 years
Brief Summary
Many reports of clinical outcomes following treatment of localized prostate cancer suffer from lack of prospective long-term data using objective and validated outcome instruments. The purpose of this...
Eligibility Criteria
Inclusion
- Males, ages 40-95
- Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy
- Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) that select focal HIFU prostate ablation as their treatment option will be offered inclusion into this prospective data collection research database.
- Patients who have early (Gleason 6 or 7), low grade cancer that is confined to the prostate.
- Willing and able to provide consent.
Exclusion
- Patients that are not diagnosed with prostate cancer.
- Patients that are diagnosed with clinically localized prostate cancer, but select other tratment options as their desired treatment.
- Patients that are not willing or are not able to give consent.
Key Trial Info
Start Date :
May 16 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2050
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07203482
Start Date
May 16 2024
End Date
December 31 2050
Last Update
October 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
NYU Langone Health - Cobble Hill
Brooklyn, New York, United States, 11201
2
NYU Langone Health - Tisch Hospital
New York, New York, United States, 10016